Open access
Open access
Powered by Google Translator Translator

Allergy & Immunology

Cohort study: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S. 11 excess venous thromboembolic events per 100 000 vaccinations; 2.5 excess cerebral venous thrombosis per 100 000 vaccinations.

7 May, 2021 | 08:33h | UTC

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study – The BMJ

Editorial: Thromboembolism and the Oxford-AstraZeneca vaccine – The BMJ

Commentaries: Thrombosis and bleeding after the Oxford-AstraZeneca covid-19 vaccination – The BMJ Opinion AND Putting risks into context: covid-19 vaccines and blood clots – The BMJ Opinion AND Expert reaction to study from Denmark and Norway looking at rare blood clots after the Oxford-AstraZeneca vaccine – Science Media Centre

 

Commentary on Twitter

 


The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity

7 May, 2021 | 08:30h | UTC

The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity – The Lancet Respiratory Medicine

 

Commentary on Twitter

 


Observational study in Qatar: Pfizer–BioNTech Covid vaccine is 89.5% effective against B.1.1.7 variant and 75.0% effective against B.1.351 variant. Vaccine effectiveness against severe, critical, or fatal disease with any SARS-CoV-2 variant was very high, at 97.4%.

6 May, 2021 | 09:06h | UTC

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants – New England Journal of Medicine

Commentary: Pfizer-BioNTech vaccine offers strong protection against key variants of concern, real-world data from Qatar shows – The Washington Post

 

Commentary on Twitter

 


Organ transplant recipients remain vulnerable to Covid-19 even after second vaccine dose.

6 May, 2021 | 09:03h | UTC

Organ Transplant Recipients Remain Vulnerable to Covid-19 Even After Second Vaccine Dose – Johns Hopkins Medicine

Original Study: Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients – JAMA

 


Cohort study shows inadequate antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients.

6 May, 2021 | 09:01h | UTC

Antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients – Prospective cohort study – Clinical Microbiology and Infection

 

Commentary on Twitter

 


[Preprint] SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity

5 May, 2021 | 08:40h | UTC

SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity – medRxiv

Commentary: SARS-CoV-2 antibodies are detectable up to a year after infection, finds study – News Medical

 

Commentary on Twitter

 


Prior SARS-CoV-2 infection boosts response to variants after first vaccine dose

4 May, 2021 | 08:51h | UTC

Prior SARS-CoV-2 infection boosts response to variants after first vaccine dose – Imperial College London

Original study: Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose – Science

 

Commentary on Twitter (thread – click for more)

 


Study: Most patients who develop a non-IgE-mediated hypersensitivity reaction to nafcillin can be safely treated with cefazolin

4 May, 2021 | 08:36h | UTC

Tolerability of Cefazolin in Nafcillin-Intolerant Patients for the Treatment of Methicillin-Susceptible Staphylococcus aureus Infections – Clinical Infectious Diseases

Related: Systematic Review and Meta-analysis of the Safety of Antistaphylococcal Penicillins Compared to Cefazolin – Antimicrobial Agents & Chemotherapy

 

Commentary on Twitter

 


Case series of 12 patients with cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination – all women younger than 60 years, with symptoms from 6 to 15 days after vaccination

3 May, 2021 | 05:43h | UTC

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021 – JAMA

Editorial: Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine – JAMA

See also: Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021 – Centers for Disease Control and Prevention AND Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021 – Centers for Disease Control and Prevention

Related: AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.”

 


Review: Systemic and organ-specific immune-related manifestations of COVID-19 – over 70 different systemic and organ-specific immune-related disorders have been reported

28 Apr, 2021 | 08:42h | UTC

Systemic and organ-specific immune-related manifestations of COVID-19 – Nature Reviews Rheumatology

 


Long Covid: Largest post-acute COVID-19 study to date examined the health outcomes in more than 73,000 people who’d had COVID-19 and were not hospitalized

23 Apr, 2021 | 08:48h | UTC

High-dimensional characterization of post-acute sequalae of COVID-19 – Nature

Commentary: Among COVID-19 survivors, an increased risk of death, serious illness – Washington University School of Medicine

 

Commentary on Twitter (thread – click for more)

 


RCT: Single-Dose Johnson & Johnson Vaccine has 85% efficacy against severe/critical Covid-19 and maintains efficacy against variant B.1.351

22 Apr, 2021 | 08:50h | UTC

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 – New England Journal of Medicine

 


Guideline: Diagnosis and Evaluation of Hypersensitivity Pneumonitis

22 Apr, 2021 | 08:21h | UTC

Diagnosis and Evaluation of Hypersensitivity Pneumonitis: CHEST Guideline and Expert Panel Report – CHEST

See also: Executive Summary

 


Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

22 Apr, 2021 | 08:40h | UTC

Post-acute COVID-19 outcomes in children with mild and asymptomatic disease – The Lancet Child & Adolescent Health

 

Commentaries on Twitter

 


ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia

21 Apr, 2021 | 07:11h | UTC

ISTH Interim Guidance for the Diagnosis and Treatment on VaccineInduced Immune Thrombotic Thrombocytopenia (Updated 20 April, 2021) – International Society on Thrombosis and Haemostasis

See also: Diagnostic Flow Chart

 

Commentary on Twitter

 


COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets

21 Apr, 2021 | 07:07h | UTC

COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets – European Medicines Agency

Commentary: Johnson & Johnson vaccine: EU regulator says blood clot very rare side effect – BBC

 

Commentary on Twitter

 


[News release – not published yet] Sputnik V demonstrates 97.6% efficacy according to the analysis of data of 3.8 million vaccinated persons in Russia

20 Apr, 2021 | 06:08h | UTC

Sputnik V demonstrates 97.6% efficacy according to the analysis of data of 3.8 million vaccinated persons in Russia

 

Commentary on Twitter

 


Pfizer CEO says third Covid vaccine dose likely needed within 12 months

20 Apr, 2021 | 06:02h | UTC

Pfizer CEO says third Covid vaccine dose likely needed within 12 months – CNBC

Commentary: Fully Vaccinated? Get Ready For Your Third Dose – Forbes

 


China’s Sinovac COVID-19 vaccine 67% effective in preventing symptomatic infection, 85% effective in preventing hospitalizations and 80% effective in preventing deaths – Chile govt report

18 Apr, 2021 | 21:45h | UTC

China’s Sinovac COVID-19 vaccine 67% effective in preventing symptomatic infection – Chile govt report – Reuters

 

Commentary on Twitter (thread – click for more)

 


Study shows antihistamines may impair response to exercise training

16 Apr, 2021 | 06:06h | UTC

Histamine H1 and H2 receptors are essential transducers of the integrative exercise training response in humans – Science Advances

Commentary: Histamine-suppressing drugs found to reduce benefits of exercise – MedicalXpress

 

Commentary on Twitter (thread – click for more)

 


[Preprint] Risk of rare blood clotting much higher for COVID-19 than for vaccines

16 Apr, 2021 | 06:37h | UTC

News release: Risk of rare blood clotting higher for COVID-19 than for vaccines – University of Oxford

Original study (preprint): Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a comparison with 489,871 people receiving a COVID-19 mRNA vaccine

Commentaries: Brain clots ‘more likely’ with Covid infection than vaccine – BBC AND Risk for Cerebral Venous Thrombosis Elevated After COVID-19 Diagnosis – NEJM Journal Watch AND Study: COVID much more likely than vaccines to cause blood clots – CIDRAP

 

Commentary on Twitter

 


Case Report: Thrombotic Thrombocytopenia after Johnson & Johnson Vaccine

15 Apr, 2021 | 07:02h | UTC

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination – New England Journal of Medicine

Related: U.S. regulators pause Johnson & Johnson vaccine rollout over rare (1 in a million) cases of blood clots AND 4 Things to Know About the J&J Covid Vaccine Pause – Kaiser Health News AND Why Johnson & Johnson shots were paused — and why that’s so confusing – Vox AND Is it the adenovirus vaccine technology, used by AstraZeneca and Johnson & Johnson, causing blood clots? There’s no evidence yet – The Conversation

 


Diagnosis and management of leukocytoclastic vasculitis

14 Apr, 2021 | 01:26h | UTC

Diagnosis and management of leukocytoclastic vasculitis – Internal and Emergency Medicine

 


RCT: Inhaled budesonide shortens recovery time in non-hospitalized patients with COVID-19

13 Apr, 2021 | 05:30h | UTC

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19 – PRINCIPLE / University of Oxford

Original study (preprint): Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial – medRxiv

Commentary: Covid: Asthma drug ‘speeds up recovery at home’ – BBC

Related study: Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19 (study and commentaries)

 


[Preprint] Pfizer vaccine less effective for SARS-CoV-2 variant B.1.351

12 Apr, 2021 | 01:26h | UTC

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals – medRxiv

Commentaries: South African variant may evade protection from Pfizer vaccine, Israeli study says – Reuters AND Israeli data shows South African variant able to ‘break through’ Pfizer vaccine – The Times of Israel

Related: Another study indicates SARS-CoV-2 variant B.1.351, but not variant B.1.1.7, has partial resistance to neutralizing antibodies generated by natural infection or mRNA vaccination AND SARS-CoV-2 variants B.1.351 and P.1 can escape from therapeutic antibodies and evade antibodies induced by infection or mRNA vaccination AND B.1.351 strain of SARS-CoV-2 neutralization titer reduced 8- to 9-fold for Pfizer and AstraZeneca vaccinees. Convalescent plasma and therapeutic antibodies were less effective against this variant as well.

 


Stay Updated in Your Specialty

No spam, just news.